hVIVO plc (AIM:HVO)

London flag London · Delayed Price · Currency is GBP · Price in GBX
8.50
-0.05 (-0.58%)
At close: Feb 27, 2026
-46.54%
Market Cap 57.83M
Revenue (ttm) 54.47M
Net Income (ttm) 5.28M
Shares Out 680.37M
EPS (ttm) 0.01
PE Ratio 11.05
Forward PE n/a
Dividend 0.00 (2.35%)
Ex-Dividend Date May 15, 2025
Volume 966,536
Average Volume 5,063,358
Open 8.55
Previous Close 8.55
Day's Range 8.30 - 8.70
52-Week Range 4.31 - 19.50
Beta 1.49
RSI 59.21
Earnings Date Apr 10, 2026

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Yamin Khan
Employees 301
Stock Exchange London Stock Exchange AIM
Ticker Symbol HVO
Full Company Profile

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.

Financial Statements

News

hVIVO plc (OPORF) Q4 2025 Sales/Trading Call Transcript

hVIVO plc (OPORF) Q4 2025 Sales/Trading Call January 29, 2026 1:00 PM ESTCompany ParticipantsYamin Khan - CEO & DirectorStephen Pinkerton - CFO &...

4 weeks ago - Seeking Alpha

Full Year 2024 hVIVO PLC Investor Presentation Transcript

Full Year 2024 hVIVO PLC Investor Presentation Transcript

4 months ago - GuruFocus

Half Year 2025 hVIVO PLC Earnings Presentation Transcript

Half Year 2025 hVIVO PLC Earnings Presentation Transcript

5 months ago - GuruFocus

Cathal Friel to step down as HVivo chairman

Cathal Friel, the co-founder of pharmaceutical services firm HVivo, formerly Open Orphan, is to step down as chairman of the group.

11 months ago - Independent Ireland

Half Year 2024 hVIVO PLC Investor Presentation Transcript

Half Year 2024 hVIVO PLC Investor Presentation Transcript

1 year ago - GuruFocus

Earnings rise 68pc at pharmaceutical services firm Hvivo

Pharmaceutical services firm Hvivo, formerly Open Orphan, has recorded a 67.6pc jump in earnings in the first six months of the year.

1 year ago - Independent Ireland